Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Announces $35 Million Offering
December 08, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the...
Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
October 11, 2022 07:00 ET
|
Cabaletta Bio
– Company has obtained exclusive worldwide license for a fully human CD19 binder with clinical tolerability data that support potential clinical development in autoimmune diseases – – CABA-201...
Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy
October 06, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
September 26, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
September 10, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 06, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial
August 29, 2022 13:58 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...